Padeliporfin

Padeliporfin
Clinical data
Trade names	Tookad
Other names	WST-09, WST-11
Drug class	Antineoplastic agent
ATC code	L01XD07 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only); EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 3-[(2S,3S,12R,13R)-8-acetyl-13-ethyl-20-(2-methoxy-2-oxoethyl)-3,7,12,17-tetramethyl-18-(2-sulfoethylcarbamoyl)-2,3,12,13-tetrahydroporphyrin-22,24-diid-2-yl]propanoic acid;palladium(2+);
CAS Number	759457-82-4;
PubChem CID	56841556;
DrugBank	DB15575;
UNII	EEO29FZT86; JQ72VD4XUL;
KEGG	D10973;
CompTox Dashboard (EPA)	DTXSID20997307 ;
Chemical and physical data
Formula	C37H43N5O9PdS
Molar mass	840.26 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1[C@H](C2=NC1=CC3=C(C(=C([N-]3)C(=C4[C@H]([C@@H](C(=N4)C=C5C(=C(C(=C2)[N-]5)C(=O)C)C)C)CCC(=O)O)CC(=O)OC)C(=O)NCCS(=O)(=O)O)C)C.[Pd+2];
	InChI InChI=1S/C37H45N5O9S.Pd/c1-8-22-17(2)25-16-30-33(21(6)43)19(4)27(40-30)14-26-18(3)23(9-10-31(44)45)35(41-26)24(13-32(46)51-7)36-34(37(47)38-11-12-52(48,49)50)20(5)28(42-36)15-29(22)39-25;/h14-18,22-23H,8-13H2,1-7H3,(H5,38,39,40,41,42,43,44,45,47,48,49,50);/q;+2/p-2/t17-,18+,22-,23+;/m1./s1; Key:MZRDSGWDVDESRC-VNWQTDIGSA-L;

Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer.^[1]^[2] It is used in the form padeliporfin di-potassium.^[2]

The most common side effects include problems with urinating (pain, inability to pass urine, strong urge to pass urine, frequent urination, and incontinence), sexual problems (erectile dysfunction and ejaculation failure), blood in urine, urinary tract infection, and pain and bleeding around the genital area.^[2]

Padeliporfin was approved for medical use in the European Union in November 2017.^[2]

^ ^a ^b "Tookad 183 mg powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 20 March 2020. Retrieved 1 April 2020.
^ ^a ^b ^c ^d ^e "Tookad EPAR". European Medicines Agency (EMA). 29 November 2017. Archived from the original on 20 October 2020. Retrieved 1 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Tookad_SmPC-1] "Tookad 183 mg powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 20 March 2020. Retrieved 1 April 2020.

[Tookad_EPAR-2] "Tookad EPAR". European Medicines Agency (EMA). 29 November 2017. Archived from the original on 20 October 2020. Retrieved 1 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]